- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
China Resources Pharmaceutical Group
Market Cap: HK$28.6b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.49
7D
0%
1Y
-15.1%
Luye Pharma Group
Market Cap: HK$9.8b
Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.
2186
HK$2.48
7D
2.5%
1Y
5.5%
Tong Ren Tang Technologies
Market Cap: HK$5.3b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$4.29
7D
1.4%
1Y
-10.6%
JBM (Healthcare)
Market Cap: HK$2.2b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.80
7D
2.2%
1Y
53.8%
Essex Bio-Technology
Market Cap: HK$2.2b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$3.95
7D
-4.8%
1Y
44.2%